{"filing":{"accession_number":"0001193125-26-229770","cik":"0001812364","ticker":null,"company_name":"Relay Therapeutics, Inc.","form":"8-K","filing_date":"2026-05-19","report_date":null,"primary_document":"rlay-20260519.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1812364/000119312526229770/rlay-20260519.htm"},"classifications":[{"id":126,"accession_number":"0001193125-26-229770","item_number":"7.01","item_title":"Regulation FD Disclosure.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.72,"reasoning":"The disclosure announces initial clinical data from a Phase 2 trial (ReInspire) of zovegalisib in vascular anomalies via press release and conference call. While clinical trial results can be material to investors assessing pipeline progress and regulatory prospects, this Item 7.01 Regulation FD disclosure does not fit neatly into the earnings_release category (which typically refers to periodic financial results) nor any other specific event type. The material clinical milestone warrants classification as other_material rather than a routine administrative disclosure.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:17:29.531647+00:00","company_name":"Relay Therapeutics, Inc.","ticker":null,"filing_date":"2026-05-19"},{"id":127,"accession_number":"0001193125-26-229770","item_number":"8.01","item_title":"Other Events.","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.75,"reasoning":"The disclosure reports initial Phase 2 clinical trial data for zovegalisib in vascular anomalies, including efficacy results (60% volumetric response rate in 20 evaluable patients), patient-reported outcomes (89% clinical improvement in IGIC), and safety data (low Grade 3+ adverse event rates at lower doses). While this is clinical trial progress rather than a discrete event like M\u0026A, restatement, or executive change, the positive efficacy and safety data from a Phase 2 trial would materially affect a reasonable investor's assessment of the drug candidate's development trajectory and commercial potential. The disclosure does not fit neatly into the more specific event categories (e.g., earnings_release, which typically refers to financial results), making other_material the most appropriate classification.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-05-20T02:17:29.531647+00:00","company_name":"Relay Therapeutics, Inc.","ticker":null,"filing_date":"2026-05-19"}]}